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Alzheimer’s disease (AD) is increasingly recognized as a complex neurodegenerative disease beginning
decades prior to the cognitive decline.While cognitive deficits remain the cardinal manifestation of AD, meta-
bolic and non-cognitive abnormalities, such as alterations in body weight and neuroendocrine functions, are
also present, often preceding the cognitive decline. Furthermore, hypothalamic dysfunction can also be a
driver of AD pathology. Here we offer a brief appraisal of hypothalamic dysfunction in AD and provide insight
into an underappreciated dual role of the hypothalamus as both a culprit and target of AD pathology, as well
as into new opportunities for therapeutic interventions and biomarker development.Introduction
Alzheimer’s disease (AD), the most common cause of dementia
in the elderly, is an incurable and devastating disease that has
emerged as one of the major public health threats of our times
(Alzheimer’s Association, 2015). The pathogenesis of AD re-
mains elusive, but the abnormal accumulation in the brain of
amyloid-beta (Ab), a peptide derived from the amyloid precursor
protein (APP), and of the microtubule-associated protein tau is
believed to lead to the synaptic dysfunction and neurodegener-
ation underlying the dementia (Musiek and Holtzman, 2015). AD
pathology develops decades prior to the initial cognitive symp-
toms in a preclinical or presymptomatic stage, in which Ab and
tau start to accumulate in brain as amyloid plaques and neurofi-
brillary tangles (Sperling et al., 2011). Cerebrovascular function is
also impaired in patients with early AD or at risk for AD, leading to
amismatch between the delivery of oxygen and glucose through
blood flow and the energy demands of the active brain (Iadecola,
2013). In addition, cerebrovascular dysfunction may impair the
vascular clearance of Ab and promote AD pathology (Gupta
and Iadecola, 2015). Therefore, AD is now believed to be a
continuum with gradually worsening pathological changes in
the brain that are the consequences of Ab, tau, vascular dysfunc-
tions, and other changes that take several years to decades
before manifesting with clinical symptoms. Thus, an early pre-
clinical stage is followed by mild cognitive symptoms (minimal
cognitive impairment [MCI]) before progressing to symptomatic
AD and eventually terminal dementia (Albert et al., 2011;
McKhann et al., 2011).
Since cognitive deficits are the most prominent feature of the
disease, AD research has placed emphasis on brain regions
associated with cognition and memory, such as the hippocam-
pus and entorhinal cortex (Musiek and Holtzman, 2015). How-
ever, AD patients exhibit significant non-cognitive deficits such
as weight loss, sleep-wake disorders, and neuroendocrine alter-
ations attributable to hypothalamic dysfunction (Csernansky
et al., 2006; Prinz et al., 1982; White et al., 1996). These alter-
ations can occur prior to the initial mental decline and progres-
sively worsen as the disease advances (Johnson et al., 2006;Ju et al., 2013; White et al., 1996), suggesting that they are an
intrinsic feature of AD pathophysiology. Although recent reviews
have addressed selected features of AD attributable to hypotha-
lamic dysfunction, such as systemic metabolic deficits or the
sleep abnormalities (Kiliaan et al., 2014; Musiek et al., 2015),
an appraisal of how AD affects the hypothalamus in light of
recent advances in both hypothalamic physiology and AD patho-
biology is conspicuously missing from the recent literature.
Therefore, in this article we sought to provide an integrated
view of the bidirectional relationships between hypothalamic
dysfunction and AD, building a case for the hypothalamus as a
contributor and a target of AD pathology and emphasizing its im-
plications for the early diagnosis and treatment of the disease.
Alterations in the Structure of the Hypothalamus in AD
Despite occupying only 4 cm3 of the brain, about the size of
an almond, the hypothalamus is the master coordinator of a
myriad of homeostatic functions essential for life such as growth,
reproduction, sleep, metabolism, and autonomic homeostasis
(Swaab, 1997). The hypothalamus is divided into different re-
gions, each having specific nuclei or clustering of neurons with
distinct behavioral and/or physiological roles (Figure 1) (Swaab,
1997). In the following sections, we will describe the evidence
for alterations in the hypothalamus in AD from classical neuro-
pathological to more recent neuroimaging studies.
Neuropathology
Several autopsy studies have reported amyloid plaques and
neurofibrillary tangles in the hypothalamus of AD subjects (Ta-
ble 1). One of the earliest studies (Stief, 1927) described a
70-year-old woman with dementia and a striking loss in body
weight (from 34.5 kg on presentation to 28 kg at time of death).
At autopsy, the body was noted to be completely devoid of fat
tissue, and in the brain, plaques and tangles were found not
only in the cortex but also in the paraventricular nucleus of
the hypothalamus and mammillary bodies (Stief, 1927). Since
then, several other studies have reported plaques and tangles
throughout the hypothalamus in patients with AD, including the
landmark paper of Braak and Braak (1991) on staging of ADCell Metabolism 22, November 3, 2015 ª2015 Elsevier Inc. 761
Nuclei
(Figure Label) Region Function
Select Neuropeptides
Neurotransmitters
Preoptic, lateral (A) 
and medial (B)
Anterior
Preoptic
Medial
Reproduction 
Thermoregulation
Sexual behavior
GnRH
Supraoptic (C) Anterior 
Medial
Neurosecretory Vasopressin
Oxytocin
Paraventricular (D) Anterior
Medial
Hormonal regulation 
Fluid balance  
Gastrointestinal 
Cardiovascular 
TRH
CRH
Oxytocin
Somatostatin
Anterior (E) Anterior
Medial
Thermoregulation
Sweating
?
Suprachiasmatic (F) Anterior
Medial
Circadian rhythm Vasopressin
VIP
Neurotensin
Lateral (G) Anterior 
Tuberal
Lateral
Thirst
Hunger
Arousal
Orexin
MCH
Dorsomedial (H) Tuberal
Medial
Cardiovascular 
Gastrointestinal
Systemic metabolism
NPY
Ventromedial (I) Tuberal
Medial
Satiety
Sexual behavior
BDNF
Arcuate (J) Tuberal
Medial
Appetite control NPY
AgRP
POMC
CART
Mammillary (K) Posterior
Medial
Memory Glutamate
Enkephalin
CCK
Posterior (L) Posterior
Medial
Cardiovascular Dynorphin
Tuberomamillary (M) Posterior
Lateral
Arousal
Systemic metabolism
Histamine
Figure 1. Hypothalamic Nuclei: Structure and Function
Coronal brain images illustrate the hypothalamus and the location of its nuclei (lettered) in order from most rostral (left) to caudal (right) with a description of key
functions and neurotransmitters/neuropeptides associated with each hypothalamic nuclei. Abbreviations: AgRP, agouti related peptide; BDNF, brain-derived
neurotrophic factor; CART, cocaine and amphetamine related transcript; CRH, corticotropin releasing hormone; GnRH, gonadotropin releasing hormone; MCH,
melanin concentrating hormone; NPY, neuropeptide Y; POMC, proopiomelanocortin; TRH, thyrotropin releasing hormone; VIP, vasoactive intestinal peptide.
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Table 1. Hypothalamus and AD: Select Pathological Studies
Study Subjects (n) Pathological Studies Hypothalamic Findings Key References
70-year-old woman with AD d Plaques
d NFT
d AD pathology in mammillary body
and PVN
Stief, 1927
AD (28) d Plaques
d NFT
d Posterior hypothalamus, lateral
hypothalamus and mammillary body
had worst AD pathology
d NFT more common than plaques
McDuff and Sumi, 1985
AD (4); Controls (28) d Neuronal counts d Decrease in total SCN cell number Swaab et al., 1985
AD (3); Controls (3) d NFT
d AChE histochemistry
d NFT in anterior, tuberal, and posterior
regions of the hypothalamus
d Vast majority of NFT AChE+
Saper and German, 1987
AD (17); Down syndrome (4); d Plaques
d NFT
d Plaques in all nuclei in late stages
d NFT appreciable by Braak and Braak
stage 3 in TMN
Braak and Braak, 1991
AD (5); Down syndrome (7);
Controls (4);
d Plaques (Ab42, Ab40) d Moderate amount of plaques that are
Ab42+ but Ab40
Iwatsubo et al., 1996
AD (11); AD with LBD (3);
FTD (4); Controls (8)
d glial/neuron ratio
d Vasopressin
d Neurotensin
d SCN degeneration
d Decrease in vasopressin and neurotensin
in SCN
Harper et al., 2008
AD (12); Controls (12) d Silver impregnation
d EM analysis
d Neuronal loss, loss of dendritic branches
and spines, and mitochondrial alterations
in SCN, SON and PVN
d Alterations in morphology of the
mitochondria and Golgi apparatus in SCN
Baloyannis et al., 2015
Abbreviations: AChE, acetylcholinesterase; DLB, dementia with Lewy bodies; DMH, dorsomedial nucleus; EM, electron microscopy; NFT, neurofibril-
lary tangles; LH, lateral hypothalamic area; PVN, paraventricular nucleus; SCN, suprachiasmatic nucleus; SON, supraoptic nucleus; TMN, tuberomam-
millary nucleus; VIP, vasoactive intenstinal peptide; VMN, ventromedial nucleus.
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chemistry in AD brains confirmed the presence of neuronal
loss, amyloid, and tau in the hypothalamus (Table 1). These
studies also found reductions in various neuropeptides and neu-
rotransmitters (e.g., vasopressin and neurotensin in the hypo-
thalamus) (Table 1). Therefore, the hypothalamus is a target of
AD pathology like the cortex and hippocampus.
Neuroimaging
Recent advances in neuroimaging have enabled the investiga-
tion of AD pathology in the living brain in a longitudinal fashion
that was simply not possible with postmortem analyses. Volu-
metric analysis usingmagnetic resonance imaging (MRI) demon-
strated that the brain atrophy well known to occur in cortex and
hippocampus is also found in the hypothalamus and can be
seen in the early stages of AD (Table 2). Perfusion studies using
single-photon emission computed tomography (SPECT) showed
a non-significant trend toward decreased perfusion in the
hypothalamus (Table 2); however, limitations with the study
including partial voluming and analysis of an overall small volume
of brain may have resulted in the statistically negative result
(Callen et al., 2002, 2004). Neuroimaging studies with posi-
tron emission tomography (PET) using 18F-fluorodeoxyglucose
(18FDG) as a tracer have reported deficits in glucose metabolism
in the hypothalamus of MCI or AD subjects (Table 2). Substantial
reductions in hypothalamic glucosemetabolisms have also been
reported in ‘‘presymptomatic’’ transgenic mice overexpressing
APP (Tg2576) (Niwa et al., 2002). More recently, PET imaging us-
ing amyloid or tau tracers has enabled investigators to study AD
pathology in vivo (Fodero-Tavoletti et al., 2011; Klunk et al.,2004). However, to the best of our knowledge, no studies have
thus far performed amyloid or tau imaging in the hypothalamus.
Complicating factors include the limited spatial resolution of PET
and off-target lipophilic binding of amyloid tracers, which may
make it difficult to accurately assess a small brain region like
the hypothalamus (Johnson et al., 2013; Su et al., 2015).
Alterations in Hypothalamic Function in AD
In addition to the structural abnormalities reviewed above, func-
tional studies suggest that hypothalamic dysfunction is a com-
monmanifestation of AD, often early in the disease course.While
the exact mechanisms underlying the various hypothalamic
dysfunction remain to be elucidated, it is likely to include not
only direct effects of Ab and tau on the hypothalamus but also
the vascular changes that are commonly seen in AD (Iadecola,
2013), since the release of many of the hormones and factors
from the hypothalamus and the downstream pituitary gland are
particularly sensitive to changes in the circulation (Fekete and
Lechan, 2014; Hrabovszky and Liposits, 2013). In the following
sections, we will discuss some of the common hypothalamic ab-
normalities associated with AD (Table 3), including dysfunction
of the classic hypothalamic-pituitary pathways (Figure 2), body
weight and systemic metabolism, bone metabolism, sleep-
wake/circadian rhythm, and aggression/sundown syndrome,
and will review selected studies from animal models (Table S1)
and AD subjects.
Hypothalamic-Pituitary-Adrenal Axis
Disruption of the hypothalamic-pituitary-adrenal axis (HPA)
(Figure 2) has been consistently demonstrated in AD. IncreasedCell Metabolism 22, November 3, 2015 ª2015 Elsevier Inc. 763
Table 2. Hypothalamus and AD: Select Neuroimaging Studies
MRI (Volume)
Study Subjects (n) Degree of Cognitive Dysfunction Findings Key References
Mild AD (19); Controls (16) MMSE
d Mild AD: 22.4 ± 2.5
d Decrease in gray matter
of anterior hypothalamus
Baron et al., 2001
AD (40); Controls (40) MMSE
d AD: 19.5 ± 6.9
d Decrease in hypothalamic
volume
Callen et al., 2001
Male AD (20); Female AD (20);
Male controls (20);
Female controls (20)
MMSE
d Male AD: 20.4 ± 6.2
d Female AD: 18.6 ± 5.7
d Decrease in hypothalamic
volume (mammillary bodies
and fornix) in males
d Females less affected
Callen et al., 2004
Cognitive symptoms (20);
MCI (20); AD (16); Controls (20)
MMSE
d Cognitive symptoms: 28.7
d MCI: 27.2
d AD: 24.6
d Controls: 29.1
d Atrophy or decreased volume
in fornix and mammillary bodies
in AD > MCI
Copenhaver et al., 2006
AD (73); DLB (73); Controls (73) MMSE
d AD: 21
d DLB: 22
d Controls: 29
d Grey matter loss in hypothalamus Whitwell et al., 2007
AD (26); Normal to AD (21);
Controls (127)
3MS
d AD: 76.7
d Normal to AD: 94.9
d Controls: 96.9
d Atrophy of medial basal
forebrain including hypothalamus
precedes dementia by 4-5 years
Hall et al., 2008
Mild AD (63); Controls (55) MMSE
d Mild AD: 26.1 ± 3.7
d Controls: 29.5 ± 0.7
d Decrease in hypothalamic volume
correlated with BMD loss
Loskutova et al., 2010
SPECT (Perfusion)
Study Subjects (n) Degree of Cognitive Dysfunction Findings Key References
AD (40); Controls (18) MMSE
d AD: 19.5 ± 6.9
d Controls: 28.5 ± 1.7
d Non-significant trend toward
decreased perfusion in
hypothalamus in AD
Callen et al., 2002
Male AD (20); Female AD (20);
Male controls (20);
Female controls (20)
MMSE
d Male AD: 20.4 ± 6.2
d Female AD: 18.6 ± 5.7
d Non-significant trend toward
decreased perfusion in
hypothalamus in male AD
Callen et al., 2004
18FDG-PET (Glucose Metabolism)
Study Subjects (n) Degree of Cognitive Dysfunction Findings Key References
AD (10); MCI (10); Controls (15) MMSE
d AD: 22.8 ± 1.8
d MCI: 28.4 ± 1.5
d Controls: 29.7 ± 0.5
d Reduced in mammillary bodies
in MCI and AD
Nestor et al., 2003
MCI (12); Controls (23) MMSE
d MCI: not reported
d Controls: 26–30
d Reduced in the hypothalamus
in MCI
Cross et al., 2013
Abbreviations: MCI, mild cognitive impairment; BMD, bone mineral density; DLB, dementia with Lewy bodies; MMSE, mini mental state examination
(scale: 0 to 30 with normal range: 27 to 30); 3MS, modified mini-mental state (scale: 0 to 100 with dementia/cognitive impairment < 79).
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feedback have been reported for all stages of AD even in
early AD (Csernansky et al., 2006; Davis et al., 1986; Greenwald
et al., 1986; Rasmuson et al., 2001) andmay be associatedwith a
more rapid disease progression (Csernansky et al., 2006; Swan-
wick et al., 1996). Various transgenic mice with increased brain
Ab deposition (e.g., TgCRND8 and Tg2576) exhibited evidence
of increased HPA axis activation at an early age (Carroll et al.,
2011; Touma et al., 2004). Additionally, acute intracerebroven-
tricular administration of Ab25-35 peptides in rats was reported
to induce memory impairment, anxiety and HPA axis hyperactiv-764 Cell Metabolism 22, November 3, 2015 ª2015 Elsevier Inc.ity (Brureau et al., 2013), suggesting that HPA axis dysfunction is
an early consequence of the amyloid presence in the brain.
A major regulator of the HPA axis is the paraventricular
nucleus of the hypothalamus through the release of the neuro-
peptide corticotropin-releasing hormone (CRH), which in turn
stimulates pituitary secretion of ACTH and subsequently adrenal
secretion of glucocorticoids (Figure 2). CRH in the CSF has been
found to be increased (Banki et al., 1992), decreased (May et al.,
1987), or unchanged (Pomara et al., 1989) in AD subjects. Rela-
tively small postmortem studies of AD brains have also yielded
mixed results (Bissette et al., 1985; Nemeroff et al., 1989; Powers
Table 3. Representative Non-Cognitive Deficits Suggesting Hypothalamic Dysfunction in AD
Physiological
Parameter Abnormality Hypothalamic Nuclei
Neuropeptides/
Neurotransmitters Key References
HPA – cortisol d Increase in cortisol levels
d Insensitivity to glucocorticoid
feedback
d Altered CRH levels
d Paraventricular d CRH Csernansky et al., 2006;
Davis et al., 1986;
Swanwick et al., 1996
HPT – thyroid d Possible decrease in serum
TRH, TSH, thyroid hormone
levels but remains controversial
d Paraventricular d TRH Tan and Vasan, 2009;
Yong-Hong et al., 2013
HPG – estrogen and
testosterone
d Low estrogen or testosterone
d Insensitivity to gonadal
hormone feedback
d Increase in LH
d Supraoptic
d Paraventricular
d GnRH Manly et al., 2000; Moffat et al.,
2004; Rodrigues et al., 2008;
Short et al., 2001
Body weight d Decrease in late-life prior
to cognitive decline
d Decrease correlates with
disease progression morbidity
and mortality
d Mid-life obesity associated
with increased risk for AD
d Arcuate
d Ventromedial
d Lateral Area
d Dorsomedial
d Leptin
d Leptin receptor
d NPY / AgRP
d POMC
d aMSH
Barrett-Connor et al., 1996;
Ewers et al., 2012; Johnson
et al., 2006; Vidoni et al., 2011;
White et al., 1998; Whitmer
et al., 2008
Circadian rhythm d Abnormal circadian locomotor
and core-body temperature
rhythms
d Suprachiasmatic d Vasopressin
d Neurotensin
d VIP
Harper et al., 2001, 2008;
Hu et al., 2013; van Someren
et al., 1996
Sleep d Fragmented sleep pattern
and reduced sleep time
d EEG changes
d Intermediate nucleus
(ventrolateral preoptic area)
d Lateral area
d Galanin
d Orexin
d MCH
Ju et al., 2013; Liguori et al.,
2014; Lim et al., 2014; Prinz et al.,
1982; Schmidt et al., 2013
Bone metabolism d Decreased bone density d Paraventricular
d Dorsomedial
d Arcuate
d HPG – Estrogen
and Testosterone
d Leptin (?)
d NPY (?)
Loskutova et al., 2010;
Yaffe et al., 1999
Abbreviations: HPA, hypothalamic-pituitary-adrenal axis; HPT, hypothalamic-pituitary-thyroid axis; HPG, hypothalamic-pituitary-gonadal axis; aMSH,
alpha melanocyte stimulating hormone; AgRP, agouti related peptide; NPY, neuropeptide Y; POMC, proopiomelanocortin; CRH, corticotropin
releasing hormone; MCH, melanin concentrating hormone; TRH, thyrotropin releasing hormone; GnRH, gonadotropin releasing hormone; VIP, vaso-
active intestinal peptide.
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tions that are appropriately powered. However, in a transgenic
mouse model of AD, chronic stress can induce tau pathology,
neurodegeneration, and learning impairments, which can be
blocked by CRH receptor 1 antagonists and enhanced by CRH
overexpression (Carroll et al., 2011). These data suggest that
the increases in CRH and the HPA axis could contribute to brain
dysfunction in AD, but supportive evidence in humans is still
missing.
Hypothalamic-Pituitary-Thyroid Axis
Although both hypothyroidism or hyperthyroidism have long
been associated with cognitive impairment and increased risk
of AD (Tan and Vasan, 2009), the link between the hypothalam-
ic-pituitary-thyroid (HPT) axis and AD remains not well under-
stood. With an intact HPT axis, low circulating thyroid hormones
stimulate production of thyrotropin releasing hormone (TRH)
from the hypothalamus and thyroid stimulating hormone (TSH)
from the pituitary to increase thyroid hormone production
(Figure 2). Studies measuring TRH levels in the CSF have re-
ported either increases (Banki et al., 1992) or decreases (Oram
et al., 1981) in AD subjects, while a postmortem study found
no differences in the hypothalamus and extra-hypothalamic
areas (Yates et al., 1983). Similarly, studies in which TSH and thy-roid hormones were measured reported increases, decreases,
or no differences in AD (Ganguli et al., 1996; Johansson et al.,
2013; Parsaik et al., 2014; Quinlan et al., 2010; Tan et al., 2008;
van Osch et al., 2004). More appropriately, one study evaluated
the function of the entire HPT axis by measuring serum TRH,
TSH, and thyroid hormones in AD subjects (Yong-Hong et al.,
2013) and found levels lower than controls. Since no TRH or
TSH increases were seen, the findings suggest a dysfunction
at the hypothalamic and/or pituitary levels resulting in a hypothy-
roid state. Based on these results, AD pathology could lead to
neuronal dysfunction in the hypothalamus, causing a decrease
in TRH, or insensitivity to low thyroid levels, which, in turn, would
decrease TSH secretion from the pituitary and ultimately reduce
thyroid hormone, causing hypothyroidism. On the other hand,
the hypothyroid state could exacerbate AD pathology (Tan and
Vasan, 2009). There is evidence that TRH and thyroid hormones
are neuroprotective against AD pathology. For example, TRH
administration to hippocampal neurons resulted in a decrease
in GSK-3b and tau phosphorylation, while TRH knockdown
increases both (Luo and Stopa, 2004). Analogs of TRHwere neu-
roprotective in glutamate and Ab toxicity in neuronal cultures
(Faden et al., 2005). Administration of L-thyroxine in mice in
which Ab was microinjected in the hippocampus prevented theCell Metabolism 22, November 3, 2015 ª2015 Elsevier Inc. 765
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Figure 2. Hypothalamic-Pituitary Pathways Affected in AD
The normal homeostatic regulation of the hypothalamic-pituitary pathways due to stimulatory (+) and inhibitory () signals is shown. That is, for the hypothalamic-
pituitary-adrenal pathway, the hypothalamus releases CRH, which stimulates (+) the secretion of ACTH from the pituitary gland. The ACTH then stimulates (+)
release of cortisol from the adrenal glands. The cortisol would then send negative feedback signals () to both the hypothalamus and pituitary gland to inhibit the
any further release of CRH and ACTH, respectively. Similar homeostatic regulation occurs with the HPT and HPG axes. Abbreviations: ACTH, adrenocorticotroic
hormone; CRH, corticotropin-releasing hormone; FSH, follicle-stimulating hormone; LH, luteinizing hormone; TSH, thyroid-stimulating hormone; T3, triiodo-
thyronine; T4, thyroxine. Figure was adapted and modified from original (Ishii, 2014).
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Therefore, HPT dysfunction could be both a cause and a conse-
quence of AD pathology.
Hypothalamic-Pituitary-Gonadal Axis
The natural aging process results in alterations of the hypo-
thalamic-pituitary-gonadal (HPG) axis (Figure 2), leading to a
dramatic decline in estrogen in women and a gradual decline
in testosterone in men (Vest and Pike, 2013). It has been hypoth-
esized that these alterations of the HPG axis, particularly low
estrogen in postmenopausal women, could precipitate AD or
contribute to its progression (Vest and Pike, 2013). Both low es-
trogen in women (Manly et al., 2000) and low testosterone inmen
have been consistently associated with poor cognitive perfor-
mance and increased risk of AD (Moffat et al., 2004; Yaffe
et al., 2002). Conversely, several studies have supported a role
of testosterone and estrogen in protecting against neurode-
generation and cognitive decline by improving synaptic function,
preventing neuronal death, and inhibiting Ab accumulation and/
or tau hyperphosphorylation (Vest and Pike, 2013). Unfortu-
nately, testosterone or estrogen supplementation trials have
not demonstrated consistent improvements in cognitive function
or delay in AD progression (Emmelot-Vonk et al., 2008; Espeland
et al., 2013; Lu et al., 2006; Shumaker et al., 2003). One possible
explanation for the failure, particularly of estrogen replacement
in early trials, is that the estrogen treatment began too late.
It has been suggested that there is a ‘‘critical period’’ or ‘‘window
of opportunity’’ where estrogen replacement would have to
occur in close temporal proximity to menopause to be beneficial
(McCarrey and Resnick, 2015). Recently, two large clinical trials
tested this ‘‘critical period’’ hypothesis, but these studies found
that hormonal replacement neither harmed nor provided any
benefit to cognition in women with early menopause (Espeland
et al., 2013; Gleason et al., 2015). Additionally, the enthusiasm766 Cell Metabolism 22, November 3, 2015 ª2015 Elsevier Inc.for testosterone or estrogen supplementation has waned as
the potential harmful consequences of long-term sex hormone
therapy in older men and women have become increasingly
recognized (Rossouw et al., 2002; Vigen et al., 2013).
While age-related changes in the HPG axis have focused on
the sharp decline in estrogen and testosterone, loss of the hypo-
thalamic negative feedback from the sex hormones has also
been implicated in AD (Rossmanith et al., 1994). Furthermore,
hypothalamic dysfunction leading to gonadotropin releasing
hormone (GnRH) signaling deficits could also play a role. Several
reports have demonstrated cognitive improvement with modula-
tion of GnRH signaling in animal models and AD subjects (Bowen
et al., 2015; Zhang et al., 2013). In one study, CSF GnRH levels
were found to be significantly reduced in AD (Oram et al.,
1981). However, a study in transgenic mice with amyloid pa-
thology found dramatic increases in GnRH expression in the
hippocampus, which were attenuated by Lupron, a GnRH super-
agonist that downregulates GnRH receptors (Nuruddin et al.,
2014). Unfortunately, the GnRH levels in the hypothalamus
were not reported in this study. Therefore, it remains unclear if
dysfunction of the feedback loop in the HPG axis contributes
to AD pathophysiology.
A recent study in mice found that aging causes hypotha-
lamic NF-kb-driven inflammation leading to decrease in GnRH
signaling and cognitive dysfunction, which was rescued by
GnRH replacement therapy (Zhang et al., 2013). This important
study highlights a potential role of reduced hypothalamic
GnRH in aging and possibly AD, but the downstream effectors
of its beneficial actions remain unclear. For example, luteinizing
hormone (LH), a gonadotropin secreted by the pituitary in
response to GnRH, may exacerbate AD pathology. Thus, several
studies have suggested an association between increased LH
levels and cognitive decline and AD (Rodrigues et al., 2008; Short
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amyloidosis and cognitive impairment (Berry et al., 2008; Bowen
et al., 2004), while LH receptor deficiency in transgenic mice
overexpressing APP significantly decreased amyloid load and
tau hyperphosphorylation (Lin et al., 2010). Recently, a Phase 2
clinical trial found that high doses of Lupron, which decreases
LH, in combination with an acetylcholinesterase inhibitor stabi-
lized the cognitive decline in mild to moderate AD (Bowen
et al., 2015). Thus, modulation of the HPG axis and in particular
GnRH signaling are potential therapeutic targets in AD, but a bet-
ter appreciation of the downstream effector mechanisms is
needed (e.g., LH), since they may be harmful.
Body Weight and Systemic Metabolism
Weight loss is commonly seen in AD patients and correlates
with disease severity and mortality (White et al., 1996, 1998).
Furthermore, low body mass index (BMI) has been associated
with worsening AD pathology in postmortem brains (Buchman
et al., 2006; Vidoni et al., 2011) and worsening CSF biomarkers
(tau and Ab1-42) in vivo (Ewers et al., 2012). Importantly, there
is substantial evidence that late-life weight loss or low body
weight can be seen prior to the cognitive decline (Barrett-Connor
et al., 1996; Buchman et al., 2005; Gao et al., 2011; Johnson
et al., 2006; Stewart et al., 2005). Furthermore, once cognitive
impairment or dementia develops, low body weight or a further
decrease in body weight is associated with worsening morbidity
and mortality, while increased body weight may be protective
(White et al., 1998). In contrast to late-life weight loss, mid-life
weight gain and obesity are associated with an increased risk
of AD (Whitmer et al., 2005), independent of other cardiovascular
risk factors (Whitmer et al., 2008; Xu et al., 2011). However, a
recent large UK population study found that mid-life obesity de-
creases AD risk, while low body weight in mid-life is associated
with an increased risk (Qizilbash et al., 2015), suggesting a com-
plex interaction between body weight and AD. Clearly, a better
understanding of the pathways by which systemic metabolism
and body weight can influence AD risk is needed (Kiliaan et al.,
2014). However, that late-life weight loss can portend AD has
been consistently reported in several different study populations
(Barrett-Connor et al., 1996; Buchman et al., 2005; Gao et al.,
2011; Johnson et al., 2006; Stewart et al., 2005) making it likely
to be an early manifestation of AD linked to the pathophysiology
of the disease.
The exact mechanisms underlying the body weight loss in AD
are not known. Owing to its major role as integrator of peripheral
metabolic signals (e.g., glucose, insulin, leptin, etc.) and as
regulator of body weight and systemic metabolism (Williams
and Elmquist, 2012), the hypothalamus is likely to be a major
driver of the weight loss in AD. Increasing evidence suggests
that leptin, an adipocyte-derived hormone that acts on the hypo-
thalamus as a negative afferent signal to maintain body weight
and energy homeostasis (Friedman and Mantzoros, 2015), is
involved in AD. Low plasma leptin levels have been associated
with increased risk of AD and cognitive decline (Holden et al.,
2009; Lieb et al., 2009). Similar to the early weight loss seen in
AD, transgenic mice overexpressing APP (Tg2576) exhibited
low body weight, due to reduced fat mass, and low plasma leptin
levels prior to amyloid plaque formation and cognitive deficits
(Ishii et al., 2014). In hypothalamic slices from Tg2576 wild-
type slices exposed to Ab1-42, the electrophysiologicalresponses to leptin were abnormal in leptin-responsive NPY-
expressing arcuate neurons, suggesting that Ab-induced hypo-
thalamic dysfunction may underlie the early body weight and
systemic metabolic deficits (Ishii et al., 2014). Conversely, other
studies found that leptin supplementation ameliorates, while
leptin receptor deficiency exacerbates, the cognitive deficits
and amyloid pathology in transgenic mice (Greco et al., 2010;
Pe´rez-Gonza´lez et al., 2014; Takeda et al., 2010). Collectively,
these studies suggest that early in AD, Ab1-42 can potentially
cause hypothalamic dysfunction in cells critical for leptin
signaling resulting in low body weight and low adiposity. The
hypothalamic dysfunction caused by Ab1-42 could lead to an
inability to sense the low plasma leptin levels resulting from
low adiposity. This lack of response to the normal feedback sig-
nals would lead to the persistence of the low body weight and
pathologically low leptin state. The low leptin levels may also
contribute to cognitive deficits in AD, because leptin has benefi-
cial effects on cognition by improving synaptic and hippocampal
function, decreasing Ab load, and reducing tau hyperphosphor-
ylation in cell and animal models (Doherty et al., 2013; Greco
et al., 2010). Beside leptin, other peripheral hormones involved
in regulating systemic metabolism and body weight (e.g., adipo-
nectin, ghrelin, and insulin; see below) have their main site of
action in the hypothalamus and as such may also play a role (Ki-
liaan et al., 2014; Moon et al., 2011). Alternatively, since olfactory
and taste deficits are common in AD (Doty et al., 1987; Velayud-
han, 2015), the weight loss could be due to decreased appetite
secondary to these deficits. However, at least in mouse models,
the early body weight deficits were found to be from increased
metabolism not reduced food intake (Ishii et al., 2014). Longitu-
dinal study in humans investigating how the olfactory/taste
changes in AD affects appetite and body weight are clearly
needed to evaluate the contribution of changes in olfaction and
taste to the weight loss in AD.
In addition to changes in body weight, recent epidemiological
studies have found that diabetes, particularly in mid-life, is asso-
ciated with an increased risk of developing AD (Biessels et al.,
2006; Kim and Feldman, 2015; Ott et al., 1999). There is also
accumulating evidence to suggest that insulin resistance in the
brain may have a significant role in AD pathobiology with some
labeling sporadic AD as ‘‘type 3 diabetes’’ (de la Monte, 2014).
Insulin receptors are widely expressed in the brain including
the olfactory bulb, cortex, hippocampus, amygdala, and hypo-
thalamus (Ghasemi et al., 2013; Kim and Feldman, 2015; Unger
et al., 1991), and insulin signaling has important roles in the regu-
lation of body weight and systemic metabolism, reproduction,
cognition, and memory (Ghasemi et al., 2013). Importantly, there
is significant evidence that insulin regulates Ab and tau, while Ab
can disrupt insulin signaling (Kim and Feldman, 2015; de la
Monte, 2014). Based on these observations, insulin signaling
has been proposed as a therapeutic target of AD, and treatment
with insulin has been demonstrated to have beneficial effects
on AD pathology and cognition in animal and human studies
(Claxton et al., 2015; Kim and Feldman, 2015; Vandal et al.,
2014). Due to the widespread expression of insulin receptors in
the hypothalamus and the critical importance of the hypothala-
mus in brain insulin signaling, the hypothalamus is well-posi-
tioned to serve as the critical link between diabetes/impaired
insulin signaling and AD.Cell Metabolism 22, November 3, 2015 ª2015 Elsevier Inc. 767
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High-fat diets, particularly those high in saturated fatty acids,
which are often associated with obesity and insulin-resistant
diabetes, have been associated with increased AD risk and
exacerbation of AD pathology in several animal and human
studies (Julien et al., 2010; Morris and Tangney, 2014; Refolo
et al., 2000). As high-fat diets, mid-life obesity, and diabetes
have all been associated with an increased risk of developing
AD, it is perhaps not surprising that caloric restriction particularly
earlier in life has been shown to be protective against AD pa-
thology and aging-related disorders in various animal models
(Halagappa et al., 2007; Mattson, 2012; Patel et al., 2005). For
example, reducing caloric intake to 60% of ad libitum fed mice
in ADmousemodels (APP+PS1 and J20) significantly decreased
the accumulation of amyloid plaques and astrocytic inflamma-
tion (Patel et al., 2005). Similarly, reduction of caloric intake in
the 3xTg triple-transgenic mouse model of AD significantly
improved the performance in the water maze and had lower
levels of Ab1-42, Ab1-40, and phospho-tau in the hippocampus
(Halagappa et al., 2007). Interestingly, intermittent fasting by
depriving food for 24 hr every other day in the 3xTg mice
improved the performance of the mice in the water maze, but
did not alter levels of Ab1-42, Ab1-40, and phospho-tau, sug-
gesting that the beneficial effects of intermittent fasting may
operate by a different mechanism than chronically reducing
caloric intake (Halagappa et al., 2007). In addition to mouse
models with increased amyloid deposition, caloric restriction in
a mouse model of increased tau deposition (Tg4510) performed
significantly better in the novel object recognition test and
contextual fear conditioning compared to ad-libitum-fed mice;
however, tau and phospho-tau levels were unchanged, as
were astrocyte and microglia activation markers (Brownlow
et al., 2014). Collectively, these and other studies have consis-
tently shown that caloric restriction can reduce AD-like pathol-
ogy and improve cognitive behavior; however, the mechanisms
underlying this beneficial effect are not known, but may include
reducing cellular stress, altering systemic metabolism, and
changing hormonal balance (e.g., increased insulin sensitivity)
(Mattson, 2012). It has been proposed that the hypothalamus
has a vital role in the benefits seen with caloric restriction
(Dacks et al., 2013). Evidence to support a hypothalamic role
include the loss of caloric-restriction-mediated anti-tumor ef-
fects in NPY knockout mice and mice with lesions of the hypo-
thalamic arcuate nuclei by monosodium glutamate, suggesting
the importance of hypothalamic pathways that regulate appetite
and systemic metabolism in mediating the beneficial effects of
caloric restriction (Minor et al., 2011). Caloric restriction also
upregulates the mammalian nicotinamide adenine dinucleotide
(NAD)-dependent deacetylase SIRT1, a key mediator of meta-
bolism and lifespan, in the dorsomedial and lateral hypo-
thalamus, where it is hypothesized to play an important role in
regulating aging and longevity (Satoh et al., 2010, 2013). The
exact mechanisms underlying the beneficial effects of caloric
restriction still remain to be elucidated, but the current evidence
strongly suggests that the hypothalamus is likely to play a signif-
icant role.
Bone Metabolism
Bone loss as measured by bone mineral density has been
associated with both age-associated cognitive decline and768 Cell Metabolism 22, November 3, 2015 ª2015 Elsevier Inc.increased risk of developing AD (Tan et al., 2005; Yaffe et al.,
1999). Decreased bone density has also been found in the early
stages of AD, and this decline was associated with brain atrophy
and cognitive decline (Loskutova et al., 2009). A hypothalamic
involvement has been suggested, as the lower whole-body
bonemineral density found in early AD was positively associated
with low gray matter volume of the hypothalamus (Loskutova
et al., 2010). Therefore, hypothalamic regulation of bone meta-
bolism is emerging as another key early feature of AD. The
mechanisms underlying the bone metabolism deficits in AD are
unclear but may involve the hypothalamic-gonadal pathways,
leptin, NPY, or other factors implicated in the hypothalamic regu-
lation of bone metabolism (Sharan and Yadav, 2014).
Disruption of Circadian Rhythm
Circadian rhythm disorders are commonly reported in AD (Mu-
siek et al., 2015). The suprachiasmatic nucleus (SCN) of the
hypothalamus has long been recognized as the main biological
regulator of circadian rhythms (Saper, 2013) and, as reviewed
below, is likely to be involved in AD.
Early studies using rest-activity monitors found marked
disruption of the normal circadian rest-activity rhythm in AD
patients, which correlated with disease severity (van Someren
et al., 1996). In addition, body temperature rhythms are also
abnormal in AD (Harper et al., 2001). A prospective cohort study
using wrist actigraphy found that a decreased circadian activity
rhythm amplitude and delayed rhythms were associated with
an increased risk of MCI and dementia (Tranah et al., 2011). In
addition, detailed analysis of circadian motor activity in subjects
with mild AD found that scale-invariance/fractal patterns of
locomotor activity fluctuations (i.e., the temporal characteristics
and properties of fluctuations that remain similar over time) were
reduced in AD (Hu et al., 2009). The same group also found that
the degree of scale-invariance or fractal activity disruption was
strongly associated with the reduction of two major circadian
neurotransmitters vasopressin and neurotensin in the SCN in
postmortem AD brains (Hu et al., 2013), confirming previous
results by others (Harper et al., 2008; Stopa et al., 1999). In
addition, the amyloid plaque burden in SCN was significantly
associated with decreasing density of neurotensin-expressing
neurons (Hu et al., 2013). In contrast, another study found no
changes in SCN vasopressin levels in AD brains (Wang et al.,
2015). Irrespective of the neurotransmitters involved, these
findings implicate the SCN in the circadian rhythm disruption in
AD (Table 1).
As in humans, abnormal circadian rhythm patterns (i.e.,
increased daytime and decreased nocturnal activity levels)
have been found in TgCRND8 mice (Ambre´e et al., 2006) and
exaggerated amplitude and alterations in core body temperature
rhythms in 3xTg mice (Knight et al., 2013). However, there have
been inconsistencies between animal models, which are likely
due to the differences in the strains, genetic makeup, and testing
conditions used in these studies (Coogan et al., 2013). Neverthe-
less, the functional and neuropathological studies in humans
with AD have provided strong evidence that circadian rhythm
abnormalities are commonly present in AD and linked to SCN
dysfunction.
Sleep-Wake Cycle Regulation
Closely related to the alterations in circadian rhythm are sleep
disorders such as fragmented sleep and reduced sleep, which
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Prinz et al., 1982). EEG studies of the sleep architecture of
AD subjects have found decreased rapid eye movement (REM)
and slow wave (delta) sleep (Prinz et al., 1982). In a cross-
sectional study of cognitively intact community-dwelling older
adults, self-reported shorter sleep duration and poorer sleep
quality were associated with greater Ab burden as measured
by amyloid imaging (Spira et al., 2013). A similar longitudinal
study found that self-reported reduced sleep was associated
with an increased risk of developing dementia and AD (Hahn
et al., 2014). Finally, a cross-sectional analysis of cognitively
intact normal individuals found that those who had CSF Ab1-
42 levels consistent with preclinical AD had worse sleep quality,
compared to cognitively intact CSF negative controls (Ju et al.,
2013). In agreement with human studies, transgenic mice with
increased amyloid deposition exhibited sleep disturbances
including decreased total sleep time with fragmented sleep,
decreased non-REM sleep, and altered nocturnal activity (Roh
et al., 2012; Sethi et al., 2015; Wisor et al., 2005). Collectively,
these studies highlight that sleep disturbances can occur prior
to the cognitive decline in AD.
Recently, it was hypothesized that sleep disturbances could
actually increase Ab deposition and thereby potentiate AD pro-
gression. Kang et al. (2009) used in vivo cerebral microdialysis
to measure Ab levels from brain interstitial fluid (ISF) in awake,
freelymovingmice and found that ISF Ab levels have a significant
diurnal pattern with highest levels found during the dark (awake)
phase. Studies of Ab dynamics in humans found a similar diurnal
pattern in CSF Ab levels (Huang et al., 2012). Furthermore, sleep
deprivation worsened Ab pathology in transgenic mouse
models, while administering an orexin antagonist to increase
sleep reduced amyloid plaque burden (Kang et al., 2009). These
studies established that Ab levels are tightly associated with the
sleep-wake cycle, but the exact mechanisms involved are not
known. One possibility is that increased neuronal activity during
the awake state increases Ab levels and drive Ab aggregation
(Cirrito et al., 2005). Alternatively, sleep may be important in
clearing Ab from the brain, since the clearance of exogenously
injected Ab in the mouse brain was dependent on sleep (Xie
et al., 2013). Collectively, these studies raise the intriguing
possibility that the sleep disorders caused by the AD pathology
in the early stages of the disease may potentiate amyloid depo-
sition and accelerate AD progression.
Although various brain areas and neurotransmitters/neuro-
peptides are involved in the sleep-wake cycle, the hypothalamic
neuropeptide orexin (or hypocretin) plays a major role (Sakurai,
2013). APP/PS1 transgenic mice with the orexin gene knocked
out have marked decreases in Ab pathology in the brain, while
sleep deprivation or increasing wakefulness increased Ab pa-
thology (Roh et al., 2014). Therefore, alterations in hypothalamic
orexin signaling can modulate Ab pathology presumably by
affecting sleep-wake cycles. However, recent studies in small
cohorts of AD subjects gave conflicting results. A postmortem
study found lower orexin levels in the CSF and hypothalamus
in AD (Fronczek et al., 2012), while other studies found increased
or no significant changes (Liguori et al., 2014; Schmidt et al.,
2013). Interestingly, a recent case-control study investigating
genetic variants in the orexin or orexin receptor genes found
that a polymorphism in the orexin receptor 2 gene increasedthe risk for AD (OR 2.53, 95% CI 1.10–5.80), suggesting that
genetic variations in orexin signaling could contribute to AD sus-
ceptibility either through deficits in sleep regulation or another
currently unknown mechanism (Gallone et al., 2014). One study
interestingly found no significant difference in CSF orexin
levels between AD and healthy control subjects, but CSF levels
of melanin-concentrating hormone (MCH) were significantly
elevated in AD subjects and correlated with CSF tau levels and
severity of cognitive impairment (Schmidt et al., 2013). This is
of particular interest because MCH is synthesized in the lateral
hypothalamic area and may be a key regulator of sleep-wake
states (Jego et al., 2013; Tsunematsu et al., 2014). In addition
to orexin and MCH, galanin-expressing neurons are reduced in
the intermediate nucleus or ventrolateral preoptic area of AD
brains, a lower number of neurons correlating with worsening
sleep fragmentation in both demented and non-demented older
individuals (Lim et al., 2014). Therefore, loss of this neuropeptide
may also be a factor in the sleep dysfunction. Finally, several
studies have found elevated levels of CSF epinephrine and
norepinephrine in AD, which may lead to increased arousal
and agitation that is commonly seen in AD (Elrod et al., 1997; Pe-
skind et al., 1998; Raskind et al., 1999).
Agitation/Aggressive Behaviors and Sundown
Syndrome
Agitation and aggressive behaviors are common manifestations
in AD affecting approximately 20% of those living in the com-
munity and 40%–60% of those living in institutional care settings
(Ballard and Corbett, 2013). They often lead to significant chal-
lenges in caretaking and are commonly a major factor in the de-
cision to move a person with AD to an institutional care setting.
While the exact etiology underlying the aggressive and agitation
behaviors in AD are not known, they are likely to involve the
hypothalamus. Since the early 20th century when electrical stim-
ulation of the hypothalamus in cats were demonstrated to elicit
aggressive behaviors, the hypothalamus has been long recog-
nized as an integral brain region regulating aggressive behavior
(Haller, 2013; Hess and Akert, 1955). Subsequent studies have
found that the hypothalamic stimulation results in aggressive
behaviors in nearly all animal species studied and have identified
‘‘hypothalamic attack areas’’ or specific regions of the hypothal-
amus including the lateral hypothalamic area and ventromedial
hypothalamic nucleus that when stimulated lead to different
aggressive behaviors (Haller, 2013). Furthermore, while there is
supporting data in animal studies to suggest that serotonin,
vasopressin, and other neurotransmitters such as norepineph-
rine and Substance P may have an etiological role in agitation
and aggressive behaviors, human studies—particularly in AD—
are unfortunately scarce (Haller, 2013).
Sundown syndrome or ‘‘sundowning’’ is a particular form of
agitation found commonly in demented individuals where there
is emergence or increase in neuropsychiatric symptoms such
as agitation, confusion, anxiety, and aggression in the late after-
noon, evening, or night (Khachiyants et al., 2011). The overall
reported rate of sundowning among demented patients ranges
from as low as 2.4% to as high as 66% depending on the study
(Khachiyants et al., 2011). As sundowning has features of
circadian, sleep, and agitation behavior disorders, the underlying
neurobiological mechanism has been hypothesized to be due to
dysfunction of the hypothalamus, particularly the SCNCell Metabolism 22, November 3, 2015 ª2015 Elsevier Inc. 769
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Figure 3. The Hypothalamus: Target and Culprit of AD Pathology?
Proposed mechanism depicting how abnormal accumulation of Ab and tau
in the hypothalamus can result in decreased hypothalamic signaling and
insensitivity to the normal hormonal feedback signals. Reduced hypothalamic
signaling in turn leads to alterations in critical physiological functions, including
neuroendocrine axis, systemic metabolism, and sleep/circadian rhythm,
which can potentially contribute to worsening amyloid and tau pathology and
cognitive/mental decline.
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the sundowning seen in AD patients is likely a reflection of the
neurodegeneration and pathological changes commonly seen
in the SCN in AD (Table 1). In addition, one recent report found
that AD subjects with sundowning had higher salivary cortisol
levels than AD subjects without sundowning or healthy controls,
suggesting that chronic exposure to high levels of glucocorti-
coids due to HPA axis dysregulation could play a role (Venturelli
et al., 2013). Unfortunately, current clinical management strate-
gies commonly rely on medications such as anti-psychotics,
which may have detrimental consequences, and non-pharma-
cological treatments, which may not be effective in severe cases
(Ballard and Corbett, 2013), and a better mechanistic under-
standing of these disturbances would help with the development
of more rational management strategies.
Bench-to-Bedside: Challenges and Opportunities
The evidence summarized in the previous sections indicates that
hypothalamic dysfunction plays an important role in AD and
could ultimately lead to the identification of novel biomarkers
and therapeutic targets. However, there are several issues that
remain to be addressed.
There is controversy about the exact nature of the neuroendo-
crine dysfunction in AD. For example, although the age-related
decline in estrogen and testosterone are consistently associated
with cognitive decline and AD (Manly et al., 2000; Moffat et al.,
2004; Yaffe et al., 2002), the role of the HPG axis, GnRH signaling
in particular, remains controversial. This is not surprising since
most human studies on neuroendocrine dysfunction in AD
were underpowered and did not explore the entire hypothalamic770 Cell Metabolism 22, November 3, 2015 ª2015 Elsevier Inc.endocrine axis, but only selected hormones. Another drawback
of these studies is that the diagnosis for AD often relied exclu-
sively on clinical criteria, which led to the possibility of misdiag-
nosing and misclassification, particularly in subjects with milder
symptoms (Sutphen et al., 2014). Appropriately powered studies
using neuroimaging and/or CSF biomarkers for AD diagnosis
should help address these problems. Studies in animals are
also problematic, because there is no single animal model that
recapitulates the full spectrum of pathological abnormalities
seen in AD (Webster et al., 2014). Therefore, key findings in
one model need to be verified in other models and ultimately in
humans.
An important open question concerns whether the hypotha-
lamic dysfunction in AD actually contributes to AD pathogenesis
or is simply a consequence of the underlying disease process.
The answer may be that it is both. One possibility is that, similar
to the hippocampus and cortex, abnormal accumulation of Ab
and/or tau in the hypothalamus disrupts normal hypothalamic
function leading to impairment in several downstream signals
that are important for maintaining vital physiological processes
(e.g., body weight regulation and neuroendocrine function)
(Figure 3). In this case, the hypothalamic dysfunction would
be a consequence of the underlying disease process of AD and
manifests itself based on the hypothalamic pathways affected
(e.g., neuroendocrine systems, body weight and systemic meta-
bolism, circadian/sleep cycles, and bone metabolism). Another
possibility is that hypothalamic dysfunction contributes to the
pathogenesis of AD. Many of the hypothalamic signaling path-
ways that are affected in AD, such as thyroid hormones, sex
hormones, leptin signaling, etc., have been shown to improve
synaptic function, protect against neuronal death, and inhibit
Ab accumulation and/or tau hyperphosphorylation (Fu et al.,
2010; Greco et al., 2010; Tan and Vasan, 2009; Vest and Pike,
2013). Therefore, we propose that hypothalamic dysfunction
could be both a target of AD pathology and a contributor to its
underlying causes. Whereas the initial AD pathology may lead
to hypothalamic dysfunction and its numerous disparate mani-
festations, the hypothalamic dysfunction, in turn, suppresses
neuroendocrine hormones and brain signaling mechanisms that
are important for maintaining cognitive function and for protec-
tion against AD pathology (Figure 3). This model highlighting the
importance of hypothalamic dysfunction in AD can therefore
not only explains the progressive nature of the metabolic and
non-cognitive manifestations seen in AD, but also suggests that
the disruption of the underlying hypothalamic pathways leading
to the metabolic and non-cognitive manifestations is an impor-
tant etiological factor of AD.
The dual significance of hypothalamic dysfunction in AD has
important implications both for identifying additional biomarkers
and for developing new therapies. As an early manifestation of
AD, hypothalamic dysfunction could be an attractive area to
improve AD diagnosis. First, hypothalamic deficits are often
seen in the preclinical stages of AD. This could enable earlier
diagnosis of AD and thereby increase the potential options for
possible therapeutic intervention. Second, while neuroimaging
and CSF biomarkers are rapidly increasing in sensitivity and
specificity, these modalities are expensive, somewhat invasive,
or simply notwidely available. Therefore, examinationof hypotha-
lamic function by EEG sleep studies, or plasma neuroendocrine
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approaches forADdiagnosis. Finally, biomarkersbasedon hypo-
thalamic function could potentially improve therapeutic trials in
preclinical AD.Current trials rely on cognitive endpoints to assess
therapeutic benefit, which are disrupted relatively later in AD
(Kryscio, 2014; Sperling et al., 2011). Since the hypothalamic
dysfunction seen in AD, such as body weight loss and sleep/
circadian rhythm disturbances, occur early in the disease and
worsen with disease progression, assessing hypothalamic func-
tion could provide additional information regarding the effective-
ness of the drug early in the course of the trial.
If hypothalamic dysfunction promotes AD pathogenesis, then
restoration of hypothalamic function should lead to improve-
ments not only in the specific hypothalamic disorder but also in
cognitive and memory deficits. Perhaps a striking example of
how modulating hypothalamic function could help in AD was
serendipitously provided by deep brain stimulation (DBS) studies
of the fornix/lateral hypothalamus in humans for treatment of
obesity. It was soon appreciated that the stimulation could evoke
autobiographic memories by driving activity in mesial temporal
lobe structures (Hamani et al., 2008). A phase I trial further sup-
ported that DBS of the hypothalamus could improve or at least
slow down the cognitive decline in AD subjects without any sig-
nificant adverse events (Laxton et al., 2010). These preliminary
studies provide an important proof of concept that modulation
of hypothalamic function could not only improve any neuroendo-
crine and non-cognitive deficits, but may also have direct thera-
peutic benefits on cognitive function and memory in AD. Future
clinical studies are needed to determine if targeting select hypo-
thalamic pathways affected in AD (e.g., HPG axis, sleep path-
ways, leptin, etc.), by itself or in a combinatorial fashion, leads
to similar results.
Conclusion
In this article, we briefly reviewed several decades of AD research
to evaluate the evidence for hypothalamic dysfunction in AD.
These studies span from early pathological studies identifying
the characteristic plaques and tangles in the hypothalamus of
postmortem AD brains to more recent investigations using ge-
netic mouse models to elucidate the specific hypothalamic cell
populations affected by amyloid toxicity. Although evidence
pointing to hypothalamic dysfunction has long been provided,
there has been a relative lack of attention to the hypothalamus
in AD research. While the cognitive deficits are the cardinal
manifestations of AD, it has become clear that metabolic and
non-cognitive deficits are an integral part of the disease as well
and may contribute to its pathogenesis. Focusing on the hypo-
thalamushasallowedus to tie together seeminglydisparateman-
ifestations of AD to a single brain region that has been demon-
strated to be a pathological target of AD. Thus, exploring further
the role of the hypothalamus in AD may provide new directions
in biomarker research and new therapeutic approaches. Since
the non-cognitive deficits attributable to hypothalamic dysfunc-
tion involve a wide variety of organ systems traditionally associ-
ated with different disciplines, multidisciplinary approaches by
basic scientistsandclinicianswithdiverse interestsandexpertise
would be required to move the field forward. Efforts in this direc-
tion promise to advance our understanding of an understudied
but vitally important aspect of the pathobiology of AD.SUPPLEMENTAL INFORMATION
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